Nature Communications · 2018 · 106 citations · 28 references
MedicineMolecular BiologyOncologyGene ExpressionMolecular OncologyTranscriptional RegulationCancer Cell SignalingGastric CancerNuclear Receptor SignalingNuclear ReceptorsTumor Suppressor GenesWnt SignalingCancer Signaling PathwaysEstrogen Receptor SignalingTherapeutic Target IdentificationTherapeutic Target ValidationTumor Suppressor Gene AnalysisTumor Suppressor PathwaysWnt In CancerWnt Signal Transduction
The principle factors underlying gastric cancer (GC) development and outcomes are not well characterized resulting in a paucity of validated therapeutic targets. To identify potential molecular targets, we analyze gene expression data from GC patients and identify the nuclear receptor ESRRG as a candidate tumor suppressor. ESRRG expression is decreased in GC and is a predictor of a poor clinical outcome. Importantly, ESRRG suppresses GC cell growth and tumorigenesis. Gene expression profiling suggests that ESRRG antagonizes Wnt signaling via the suppression of TCF4/LEF1 binding to the CCND1 promoter. Indeed, ESRRG levels are found to be inversely correlated with Wnt signaling-associated genes in GC patients. Strikingly, the ESRRG agonist DY131 suppresses cancer growth and represses the expression of Wnt signaling genes. Our present findings thus demonstrate that ESRRG functions as a negative regulator of the Wnt signaling pathway in GC and is a potential therapeutic target for this cancer.
28
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass, Vésteinn Thórsson, David Van Den Berg et al. · Nature · 2014 · 6.5K citations · Full text
Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer
Qing-Lin Li, Kosei Ito, Chohei Sakakura et al. · Cell · 2002 · 1K citations · Full text
Medicine, Cancer Biology, Oncology +14